Clinical trials: Psychosis; Episode
First-Episode Psychosis
Trial to Increase FEP Attendance
Individuals with first-episode psychosis (FEP) are at high-risk for several poor functional and clinical outcomes, including suicide.
- Trial name
- NCT05967195
- Testing
- Financial Incentive and Text-Messages
- Where
- 3 sites in United States
- Volunteers
- 145 people
- Sponsor
- University of Pennsylvania
Schizophrenia, Schizophreniform Disorder
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
This is a randomized controlled 6-month trial of the efficacy of a novel intervention combining neuroplasticity-based cognitive training with aerobic exercise, compared to the same systematic cognitive training alone.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- CT&E (NCT02267070)
- Testing
- Case management and supportive psychotherapy, Family psychoeducation, Cognitive training
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia
Ginkgo Biloba Extract for Schizophrenia
A double-blind, randomized, placebo-controlled trial of ginkgo biloba extract (Egb-761) as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with…
- Trial name
- NCT01524380
- Testing
- Ginkgo biloba extract
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Schizophrenia
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- NCT00207064
- Testing
- quetiapine
- Where
- 3 sites in Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Psychotic Disorder, Schizophreniform Disorder
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
Weight gain associated with antipsychotic medication use is a major side effect that limits the tolerability of these drugs. This often significant weight gain adversely affects health, increasing risks for developing…
- Conditions
- Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00287352
- Testing
- Olanzapine, Amantadine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
First Episode Psychosis (FEP)
Use of Parent Connectors in First Episode Psychosis (FEP)
This study proposes to adapt an evidence based peer parent navigator (PPN) intervention, called Parent Connectors, in which trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or…
- Trial name
- NCT04018521
- Testing
- PPN, CSC Usual Care
- Volunteers
- healthy volunteers welcome
- Sponsor
- NYU Langone Health
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Psychosis, Schizophrenia
ReMindCare App for Patients From First Episode of Psychosis Unit.
ReMindCare is an app designed by the Unit of Psychiatry at the Clinical Hospital of Valencia in liaison with the Polytechnic University of Valencia.
- Conditions
- Psychosis, Schizophrenia, Psychotic Disorders, Delirium
- Trial name
- NCT03807388
- Testing
- ReMindCare Intervention Group, Treatment as Usual
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Instituto de Investigacion Sanitaria INCLIVA